Joshua Richter, MD / Saad Z. Usmani, MD, MBA, FACP - Optimizing Patient Outcomes in Relapsed/Refractory Multiple Myeloma: The Role of Novel BCMA-Targeted Bispecific Antibodies

episode

CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

The Ezra Klein Show: Jensen Huang Thinks A.I. Alarmism Has Gone Too Far 1h 50m · 25 Sep 2026 · Hard Fork

Pretty Little Episode #110 26 min · 25 Sep 2026 · Handsome

Be Upfront About How You Make Money From Your Podcast 2 min · 25 Sep 2026 · One Minute Podcast Tips - Be a Better Podcaster in Just 60 Seconds

High Stakes US-China Sit Down & Flock Surveillance Under Scrutiny | 9.25.26 19 min · 25 Sep 2026 · Morning Wire

Ireland collapse in Kosovo as Israel game looms 13 min · 25 Sep 2026 · Today with David McCullagh

Living Breakthrough-Minded | Joel Osteen 30 min · 25 Sep 2026 · Joel Osteen Podcast

Report any issue

Source

Recorded19 Sep 2023

Publisherc.answersincme.com ↗

Handlerec:13096843

Show notes

Please visit answersincme.com/GQB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in hematology-oncology discuss B-cell maturation antigen (BCMA)–targeted therapies in the treatment of relapsed/refractory multiple myeloma. Upon completion of this activity, participants should be better able to: Identify where BCMA-targeted therapies fit into the current treatment paradigm of RRMM; Describe the clinical profiles of new and emerging BCMA-targeted bispecific antibodies in heavily treated RRMM; and Outline strategies to optimally incorporate novel BCMA-targeted bispecific antibodies into the treatment paradigm of RRMM.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in